Brave Asset Management Inc. Sells 70 Shares of Johnson & Johnson (NYSE:JNJ)

Brave Asset Management Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 0.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,760 shares of the company’s stock after selling 70 shares during the period. Brave Asset Management Inc.’s holdings in Johnson & Johnson were worth $1,216,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Meadow Creek Wealth Advisors LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $1,205,000. Syntegra Private Wealth Group LLC raised its holdings in Johnson & Johnson by 8.2% in the 4th quarter. Syntegra Private Wealth Group LLC now owns 1,882 shares of the company’s stock valued at $295,000 after acquiring an additional 143 shares in the last quarter. Brown Miller Wealth Management LLC raised its holdings in Johnson & Johnson by 1.0% in the 4th quarter. Brown Miller Wealth Management LLC now owns 18,280 shares of the company’s stock valued at $2,865,000 after acquiring an additional 183 shares in the last quarter. Ellsworth Advisors LLC raised its holdings in Johnson & Johnson by 3.9% in the 4th quarter. Ellsworth Advisors LLC now owns 10,985 shares of the company’s stock valued at $1,722,000 after acquiring an additional 412 shares in the last quarter. Finally, Saxon Interests Inc. acquired a new position in Johnson & Johnson in the 4th quarter valued at $1,313,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Up 0.1 %

NYSE JNJ opened at $158.19 on Monday. The business’s 50-day moving average price is $158.58 and its two-hundred day moving average price is $156.63. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $175.97. The firm has a market capitalization of $381.20 billion, a PE ratio of 11.45, a price-to-earnings-growth ratio of 2.66 and a beta of 0.53. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same quarter in the previous year, the company posted $2.35 EPS. The business’s revenue was down 9.7% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th were paid a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.01%. The ex-dividend date of this dividend was Friday, February 16th. Johnson & Johnson’s dividend payout ratio is 34.47%.

Analyst Ratings Changes

JNJ has been the subject of several analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 28th. Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Morgan Stanley lowered their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Finally, Raymond James boosted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Seven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $177.31.

View Our Latest Stock Report on JNJ

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.